503622596 12/22/2015

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3669227

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
SHAKER A. MOUSA	12/14/2015
PAUL J. DAVIS	12/14/2015

RECEIVING PARTY DATA

Name:	NANOPHARMACEUTICALS, LLC	
Street Address:	1 DISCOVERY DRIVE	
City:	RENSSELAER	
State/Country:	NEW YORK	
Postal Code:	12144	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	14977776

CORRESPONDENCE DATA

Fax Number: (518)220-1857

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 518-220-1850

Email: epappas@IPLAWUSA.COM
Correspondent Name: SCHMEISER, OLSEN & WATTS

Address Line 1: 22 CENTURY HILL DRIVE

Address Line 2: SUITE 302

Address Line 4: LATHAM, NEW YORK 12110

ATTORNEY DOCKET NUMBER:	NANOP.50198CON-NY	
NAME OF SUBMITTER:	ARLEN OLSEN	
SIGNATURE:	/Arlen Olsen/	
DATE SIGNED:	12/22/2015	

Total Attachments: 2

source=50198CON_ExecutedAssignment#page1.tif source=50198CON_ExecutedAssignment#page2.tif

PATENT 503622596 REEL: 037347 FRAME: 0113

ASSIGNMENT

Title of Invention: NANOPARTICLES AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF

Whereas, the undersigned inventor(s) has/have made certain inventions, improvements, and discoveries (herein referred to as the "Invention") disclosed in the above-identified patent application and further identified by the Docket Number provided above in the header of this document;

Whereas, NANOPHARMACEUTICALS, LLC, a corporation having a place of business at 1 DISCOVERY DRIVE RENSSELAER, NY 12144 (herein referred to as NANOPHARMACEUTICALS"), desires to acquire, and each undersigned inventor desires to grant to NANOPHARMACEUTICALS, the entire worldwide right, title, and interest in and to the Invention and in and to any and all patent applications and patents directed thereto;

Now, therefore, for good and valuable consideration, the receipt and sufficiency thereof being hereby acknowledged, each undersigned inventor ("ASSIGNOR") hereby sells or has sold assigns or has assigned, and otherwise transfers or has transferred to NANOPHARMACEUTICALS (the "ASSIGNEE"), its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the Invention, the above-identified United States patent application, and any and all other patent applications and patents for the Invention which may be applied for or granted therefor in the United States and in all foreign countries and jurisdictions, including all divisions, continuations, reissues, reexaminations, renewals, extensions, counterparts, substitutes, and extensions thereof, and all rights of priority resulting from the filing of such applications and granting of such patents. In addition, each undersigned inventor hereby authorizes and requests the Director of the United States Patent and Trademark Office to issue any United States Patent, and foreign patent authorities to issue any foreign patent, granted for the Invention, to NANOPHARMACEUTICALS, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the same to be held and enjoyed by NANOPHARMACEUTICALS, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by the undersigned had this Assignment not been made; and each undersigned inventor agrees to execute any and all documents and instruments and perform all lawful acts reasonably related to recording this Assignment or perfecting title to the Invention and all related patents and applications, in NANOPHARMACEUTICALS, its successors, legal representatives, and assigns, whenever requested by NANOPHARMACEUTICALS, its successors, legal representatives, or assigns.

Each undersigned inventor acknowledges their prior and ongoing obligations to sell, assign, and transfer the rights under this Assignment to NANOPHARMACEUTICALS and is unaware of any reason why they may not have the full and unencumbered right to sell, assign, and transfer the rights hereby sold, assigned, and transferred, and has not executed, and will not execute, any document or instrument in conflict herewith. Each undersigned inventor also hereby grants NANOPHARMACEUTICALS, its successors, legal representatives, and assigns,

DOCKET NUMBER: NANOP.50198CON-NY

the right to insert in this Assignment any further identification (including, but not limited to, patent Application Number) which may be necessary or desirable for recordation of this Assignment.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

(1) Legal Name of Inventor: Shaker A. Mousa

Signature:

Date: \2 |14 | 2015

(2) Legal Name of Inventor: Paul J. Davis

Signature:

7 /3= Date: 06C, 14, 2015